Mutational Disorders Pipeline Review, H2 2012 New Report
Mutational Disorders - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mutational Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mutational Disorders.
View full press release